These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1102 related items for PubMed ID: 16604479

  • 1. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 2. [Relationship between the polymorphism of start codon and CDX2 site in vitamin D receptor gene and the effect of calcium supplementation on bone mineral density of postmenopausal women].
    Zhang ZL, He JW, Huang QR, Qin YJ, Hu YQ, Li M, Zhang H, Liu YJ, Hu WW.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug; 23(4):397-401. PubMed ID: 16883525
    [Abstract] [Full Text] [Related]

  • 3. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 4. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR, Wu YY, Zhang ZL, Yang X, Hui Y, Zhang Y, Chen SL, Den WH, Liu H, Ekangaki A, Stocks J, Harper K, Liu JL.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr 17; 38(4):226-9. PubMed ID: 12885371
    [Abstract] [Full Text] [Related]

  • 5. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug 17; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 6. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 17; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 7. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Jul 17; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 8. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.
    J Bone Miner Res; 2008 Apr 17; 23(4):525-35. PubMed ID: 18072873
    [Abstract] [Full Text] [Related]

  • 9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 17; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 10. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
    Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V.
    Maturitas; 2006 Mar 20; 53(4):371-9. PubMed ID: 16139450
    [Abstract] [Full Text] [Related]

  • 11. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G.
    Int J Tissue React; 2003 Mar 20; 25(2):73-8. PubMed ID: 14518596
    [Abstract] [Full Text] [Related]

  • 12. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 20; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 13. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006 Nov 20; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 14. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 20; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 15. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
    Celi M, Letizia C, Ragno A, Minisola S, D'Erasmo E, Mazzuoli GF.
    Minerva Med; 2002 Dec 20; 93(6):471-8. PubMed ID: 12515970
    [Abstract] [Full Text] [Related]

  • 16. [Association of polymorphisms of vitamin D receptor gene start codon and 3'-end region with bone mineral density in postmenopausal women].
    Zhang ZL, Zhao JX, Meng XW, Zhou XY, Xing XP, Xia WB.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb 20; 20(1):5-8. PubMed ID: 12579489
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 20; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 18. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.
    Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR.
    Ren Fail; 2005 Jul 20; 27(2):155-61. PubMed ID: 15807179
    [Abstract] [Full Text] [Related]

  • 19. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Jul 20; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 20. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep 20; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.